TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Current Deferred Revenue of $1.6 million for Q1 2026, down 84.06% year-over-year from $10.3 million in Q1 2025, and down 37.5% quarter-over-quarter from $2.6 million in Q4 2025.
TScan Therapeutics (TCRX) Current Deferred Revenue (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Current Deferred Revenue for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 84.06% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 84.06% YoY), while the FY2025 annual figure was $2.6 million, down 77.61% from the prior year.
- Current Deferred Revenue declined to $1.6 million in Q1 2026 per TCRX's latest filing, from $2.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $19.2 million in Q2 2023 and bottomed at $1.6 million in Q1 2026.
- Historically, Current Deferred Revenue has averaged $9.0 million across 5 years, with a median of $10.0 million in 2023.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 161.67% — and 2026, when it slumped 84.06%.
- TScan Therapeutics' Current Deferred Revenue stood at $3.9 million in 2022, then jumped by 161.67% to $10.1 million in 2023, then gained by 15.4% to $11.7 million in 2024, then plunged by 77.61% to $2.6 million in 2025, then tumbled by 37.5% to $1.6 million in 2026.
- Business Quant data shows TCRX's Current Deferred Revenue at $1.6 million in Q1 2026, $2.6 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 586,000.00 |
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 5.19 Mn |
| Jun 30, 2025 | 7.70 Mn |
| Mar 31, 2025 | 10.27 Mn |
| Dec 31, 2024 | 11.70 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Jun 30, 2024 | 10.70 Mn |
| Mar 31, 2024 | 10.44 Mn |
| Dec 31, 2023 | 10.14 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | 19.21 Mn |
| Dec 31, 2022 | 3.87 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 8.17 Mn |
| Mar 31, 2022 | 10.87 Mn |
| Dec 31, 2021 | 11.41 Mn |
| Sep 30, 2021 | 11.97 Mn |
| Jun 30, 2021 | 11.75 Mn |